Lu L, Zhou X, Zheng J, Li D
J Hepatocell Carcinoma. 2025; 12:367-382.
PMID: 40008396
PMC: 11853879.
DOI: 10.2147/JHC.S500119.
Xie G, Zhong Z, Ye T, Xiao Z
BMC Surg. 2025; 25(1):47.
PMID: 39875933
PMC: 11776151.
DOI: 10.1186/s12893-025-02778-z.
Liu X, Jiang D, Liu Y, Xie K, Zhao Y, Liu F
Cytojournal. 2024; 21:53.
PMID: 39737136
PMC: 11683396.
DOI: 10.25259/Cytojournal_109_2024.
Yang Y, Zhang L, Munyurangabo G, Zhou Y, He S, Zhang P
J Cancer. 2024; 15(20):6479-6489.
PMID: 39668826
PMC: 11632984.
DOI: 10.7150/jca.97844.
Zhang F, Zhong S, Wei Q, Zhang H, Hu H, Zeng B
J Hepatocell Carcinoma. 2024; 11:1961-1978.
PMID: 39429914
PMC: 11491080.
DOI: 10.2147/JHC.S483824.
Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.
Liu B, Liu L, Liu Y
Front Immunol. 2024; 15:1450487.
PMID: 39315094
PMC: 11416969.
DOI: 10.3389/fimmu.2024.1450487.
The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion.
Tadokoro T, Tani J, Morishita A, Fujita K, Masaki T, Kobara H
Cancers (Basel). 2024; 16(14).
PMID: 39061174
PMC: 11274937.
DOI: 10.3390/cancers16142534.
Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.
Ou X, Wu J, Wu J, Fu Y, Zeng Z, Li S
Cancer Res Treat. 2024; 56(4):1207-1218.
PMID: 38697847
PMC: 11491243.
DOI: 10.4143/crt.2023.1165.
CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.
Tang C, Zhuang H, Wang W, Wang Q, Ma X, Wang B
Cell Death Dis. 2024; 15(3):191.
PMID: 38443362
PMC: 10914787.
DOI: 10.1038/s41419-024-06570-4.
Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis.
Lim M, Kim J, Rhu J, Choi G, Joh J
J Liver Cancer. 2024; 24(1):102-112.
PMID: 38351676
PMC: 10990670.
DOI: 10.17998/jlc.2024.01.31.
Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma.
Yoshida R, Koroki K, Makishima H, Ogasawara S, Ishino T, Ogawa K
Case Rep Oncol. 2023; 14(2):1103-1110.
PMID: 38075390
PMC: 10701105.
DOI: 10.1159/000517440.
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map.
Requeijo C, Bracchiglione J, Meza N, Acosta-Dighero R, Salazar J, Santero M
Clin Epidemiol. 2023; 15:1069-1085.
PMID: 38025841
PMC: 10644842.
DOI: 10.2147/CLEP.S431498.
The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer.
Zeng N, Wang Y, Wan Y, Wang H, Li N
Clin Med Insights Oncol. 2023; 17:11795549231204612.
PMID: 38023286
PMC: 10666691.
DOI: 10.1177/11795549231204612.
HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis.
Lu K, Zhao T, Yang L, Liu Y, Ruan X, Cui L
J Gastrointest Oncol. 2023; 14(5):2178-2191.
PMID: 37969822
PMC: 10643579.
DOI: 10.21037/jgo-23-447.
Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway.
Chen P, Liao Y, Cheng Y, Wu H, Wu Y, Huang M
Oncogenesis. 2023; 12(1):49.
PMID: 37907465
PMC: 10618527.
DOI: 10.1038/s41389-023-00494-y.
Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wang Y, Lau W, Li Y, Tian Y, Lei Y, Wang J
Int J Surg. 2023; 109(11):3590-3601.
PMID: 37598406
PMC: 10651248.
DOI: 10.1097/JS9.0000000000000652.
LncRNA MEG3 Inhibits Tumor Progression by Modulating Macrophage Phenotypic Polarization via miR-145-5p/DAB2 Axis in Hepatocellular Carcinoma.
Wei Q, Liu G, Huang Z, Huang Y, Huang L, Huang Z
J Hepatocell Carcinoma. 2023; 10:1019-1035.
PMID: 37435155
PMC: 10329916.
DOI: 10.2147/JHC.S408800.
Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report.
Kim I, Yoo S, Lee J, Lee K, Lee H, Lim J
J Liver Cancer. 2023; 22(1):84-90.
PMID: 37383537
PMC: 10035705.
DOI: 10.17998/jlc.2022.03.07.
Deconvolution of bulk gene expression profiles reveals the association between immune cell polarization and the prognosis of hepatocellular carcinoma patients.
Chiu Y, Ni C, Huang Y
Cancer Med. 2023; 12(14):15736-15760.
PMID: 37366298
PMC: 10417088.
DOI: 10.1002/cam4.6197.
RBM38 Reverses Sorafenib Resistance in Hepatocellular Carcinoma Cells by Combining and Promoting lncRNA-GAS5.
Gao X, Lu C, Liu Z, Lin Y, Huang J, Lu L
Cancers (Basel). 2023; 15(11).
PMID: 37296859
PMC: 10252096.
DOI: 10.3390/cancers15112897.
